Emperra Wins the 2017 Game Changers Award for Digital Business Models

Potsdam

Emperra GmbH, a start-up company based in Potsdam, Germany, has received the Finance Monthly’s 2017 Game Changers Award. The award is honouring Emperra for its new digital business models, which – based on innovative hardware – enable business revenue to be generated from digital solutions. The 2017 Game Changers Awards honour the innovation and strategic vision of a number of globally recognised specialists across a number of different industrial sectors. Read more

CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

  • Parties intend to jointly enable AAV production in CEVEC’s CAP(R)GT cells in combination with PlasmidFactory’s broad AAV serotype plasmid portfolio
  • Collaboration will significantly increase the value of CAP(R)GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications

Read more

Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO

Reinforcement of senior management team to leverage growth phase of Humedics

Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO). Read more

The Berlin Institute of Health adopts the digital laboratory data management platform from the Berlin-based start-up labfolder

The Berlin-based start-up labfolder has won a second major client: beginning in April 2017, the Berlin Institute of Health (BIH) will be introducing labfolder’s electronic lab notebook as part of its quality initiative. The innovative data management software will be made available to more than 4,000 researchers at the Charité and the Max Delbrück Center for Molecular Medicine. Read more

CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology

  • Project will cover the entire process from R&D up to manufacturing and clinical development of adenoviral vectors for medac’s oncology products using CEVEC’s proprietary CAP(R)GT Technology

  • Collaboration is next step in setting CAP(R)GT as global standard in adenoviral gene therapy

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications. Read more

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development

Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP(R)GT and CAP(R)Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections. Read more

LiMAx test enables better timing of liver surgery for colorectal liver metastatic patients after chemotherapy

Determination of liver function is crucial to assess patient’s eligibility for safe liver resection

Berlin.  Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that two studies show the potential of the LiMAx test to better assess the eligibility of colorectal cancer patients for liver metastases resection after chemotherapy. The LiMAx test was used to explore the effects of oxaliplatin-based chemotherapy on liver function. Read more

CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA

  • Submission represents an important step towards establishing CAP(R)GT and CAP(R)Go technologies as the new industrial standards for viral vaccines, commercial-scale gene therapy vectors and recombinant protein production
  • CEVEC’s CAP(R) technology licensees can reference BB-MF, simplifying and accelerating their regulatory approval process for a CAP(R)-derived product.

Read more